The DOI matches its Crossref record.
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Open accessAbstract
CONTEXT: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50-100% mortality, typically from respiratory complications. OBJECTIVES: Our objective was to better understand the effect of treatment with asfotase alfa, a first-in-class enzyme replacement therapy, on mortality in neonates and infants with severe HPP. DESIGN/SETTING: Data from patients with the perinatal and infantile forms of HPP in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of asfotase alfa treatment were compared with data from similar patients from a retrospective natural history study. PATIENTS: Thirty-seven treated patients (median treatment duration, 2.7 years) and 48 historical controls of similar chronological age and HPP characteristics. INTERVENTIONS: Treated patients received asfotase alfa as sc injections either 1 mg/kg six times per week or 2 mg/kg thrice weekly. MAIN OUTCOME MEASURES: Survival, skeletal health quantified radiographically on treatment, and ventilatory status were the main outcome measures for this study. RESULTS: Asfotase alfa was associated with improved survival in treated patients vs historical controls: 95% vs 42% at age 1 year and 84% vs 27% at age 5 years, respectively (P < .0001, Kaplan-Meier log-rank test). Whereas 5% (1/20) of the historical controls who required ventilatory assistance survived, 76% (16/21) of the ventilated and treated patients survived, among whom 75% (12/16) were weaned from ventilatory support. This better respiratory outcome accompanied radiographic improvements in skeletal mineralization and health. CONCLUSIONS: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment
Whyte, M. P. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.14 · Cited by 511
Self-citationAlkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Self-citationAlkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P., & Magnusson, P. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.60 · Cited by 316
Pyrophosphate: a key inhibitor of mineralisation
Orriss, I. R., Arnett, T. R., & Russell, R. G. G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.03.003 · Cited by 181
Dental outcomes for children receiving asfotase alfa for hypophosphatasia
Schroth, R. J., Long, C., Lee, V. H. K., Alai-Towfigh, H., & Rockman-Greenberg, C. (2021) · Bone · doi:10.1016/j.bone.2021.116089 · Cited by 29
Self-citation
Metadata
- Authors
- Whyte, M. P., Rockman-Greenberg, C., Ozono, K., Riese, R., Moseley, S., Melian, A., Thompson, D. D., Bishop, N., & Hofmann, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-01
- Volume
- 101
- Issue
- 1
- Pages
- 334-342
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150512825
- Cited by
- 266
- References
- 0
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. https://app.cochat.ai/papers/10.1210/jc.2015-3462
- The paper
- Whyte, M. P., Rockman-Greenberg, C., Ozono, K., Riese, R., Moseley, S., Melian, A., Thompson, D. D., Bishop, N., & Hofmann, C. (2016). Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-3462
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.